324 related articles for article (PubMed ID: 22466929)
1. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Imberti D; Gallerani M; Manfredini R
J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
[TBL] [Abstract][Full Text] [Related]
2. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
5. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.
Deeks ED
Drugs; 2012 Jun; 72(9):1271-91. PubMed ID: 22686618
[TBL] [Abstract][Full Text] [Related]
6. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Martin MT; Nutescu EA
Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
[TBL] [Abstract][Full Text] [Related]
8. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Pineo GF; Gallus AS; Raskob GE; Chen D; Ramirez LM; Ramacciotti E; Lassen MR; Wang L
J Thromb Haemost; 2013 Mar; 11(3):444-51. PubMed ID: 23279103
[TBL] [Abstract][Full Text] [Related]
9. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
10. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
11. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
12. Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.
Lassen MR
Drugs Today (Barc); 2012 Apr; 48(4):249-58. PubMed ID: 22536567
[TBL] [Abstract][Full Text] [Related]
13. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
15. Apixaban: a novel oral inhibitor of factor Xa.
Nutescu E
Am J Health Syst Pharm; 2012 Jul; 69(13):1113-26. PubMed ID: 22722590
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
[TBL] [Abstract][Full Text] [Related]
17. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
18. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Squizzato A; Lussana F; Cattaneo M
Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Harenberg J; Marx S; Dahl OE; Marder VJ; Schulze A; Wehling M; Weiss C
Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668
[TBL] [Abstract][Full Text] [Related]
20. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]